Granules India Ltd

Granules India announced the successful closing of the acquisition of Senn Chemicals AG, a Swiss based Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing. This marks a strategic milestone in Granules' transformation into a science- and innovation-led organization and extends its capabilities into the fast growing peptide therapeutics segment. The acquisition follows the signing of a definitive share purchase agreement in February 2025, under which Granules, through its wholly owned Indian subsidiary, Granules Peptides, acquired 100% of the equity of Senn Chemicals from the founding Senn family. Founded over 60 years ago, Senn Chemicals has built a strong reputation as a specialist in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), serving innovators and brand owners across pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Powered by Capital Market - Live

Granules India has allotted 50,000 equity shares under ESOS on 20 March 2025. Powered by Capital Market - Live

Granules India Ltd lost 3.02% today to trade at Rs 457.2. The BSE Healthcare index is down 0.24% to quote at 38485.45. The index is down 8.14 % over last one month. Among the other constituents of the index, Indoco Remedies Ltd decreased 2.87% and Sun Pharma Advanced Research Company Ltd lost 2.45% on the day. The BSE Healthcare index went up 10.88 % over last one year compared to the 0.67% fall in benchmark SENSEX. Granules India Ltd has lost 17.88% over last one month compared to 8.14% fall in BSE Healthcare index and 5.19% drop in the SENSEX. On the BSE, 4363 shares were traded in the counter so far compared with average daily volumes of 45200 shares in the past one month. The stock hit a record high of Rs 724.55 on 02 Sep 2024. The stock hit a 52-week low of Rs 382.05 on 15 Apr 2024.Powered by Capital Market - Live

Granules India announced that Sethu Madhavan Sankaran, shall cease to be the Senior Management Personnel (SMP) of the Company upon his resignation from the position of Senior Vice President & Head- API Manufacturing & Operations with effect from the closure of business hours of 28 February 2025. Powered by Capital Market - Live

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactures, Peptides and peptides based applications for its global customers, providing contract research, development, and manufacturing services. Its revenue for CY23 was CHF 26.9 million and it had estimated sales of CHF 19.6 million in the calendar year (CY) 2024. The acquisition brings Senn's expertise in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments. This acquisition enables Granules' acquiring capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn's R&D capabilities. The transaction is expected to be completed in the first half of calendar year 2025. Krishna Prasad Chigurupati, chairman & managing director, Granules India, said, The acquisition of Senn Chemicals AG marks a significant milestone in Granules' strategic growth journey. By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn's expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally. This acquisition is a pivotal moment in our vision to transform Granules to a science and innovation led organization and become a trusted partner in complex and specialized therapeutics. Rico Wiedenbruch, chairman, Senn Chemicals AG, said, We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules' scale, operational efficiency, and global reach in pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics. This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing. Meanwhile, the company's board approved incorporation of a wholly owned subsidiary in India for the aforementioned acquisition. The name of the proposed wholly-owned subsidiary (WOS) will be as approved by the Ministry of Corporate Affairs (MCA), Government of India. The company shall be incorporated with an authorized share capital of Rs 500 crore and a paid-up share capital of Rs 200 crore. Granules India is primarily involved in the manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company's consolidated net profit fell 6.41% to Rs 117.60 crore on 1.55% decline in total revenue from operations to Rs 1,137.70 crore in Q3 FY25 over Q3 FY24.Powered by Capital Market - Live

The key equity benchmarks traded with significanct losses in early trade. The Nifty traded below the 22,650 mark. Barring pharma index all the sectoral indices traded in red with realty, media and IT shares declining the most. At 09:25 IST, the barometer index, the S&P BSE Sensex, declined 540.49 points or 0.72% to 74,759.17. The Nifty 50 index shed 172.95 points or 0.76% to 22,622.95. In the broader market, the S&P BSE Mid-Cap index rose 1.56% and the S&P BSE Small-Cap index added 1.96%. The market breadth was weak. On the BSE, 722 shares rose and 2,287 shares fell. A total of 135 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 3,449.15 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 2,884.61 crore in the Indian equity market on 21 February 2025, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper advanced 1.52% to 6.810 as compared with the previous close of 6.700. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 86.6600, compared with its close of 86.6825 during the previous trading session. MCX Gold futures for 4 April 2025 settlement were added 0.16% to Rs 86.090. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.41% to 106.17. The United States 10-year bond yield added 0.34% to 4.435. In the commodities market, Brent crude for April 2025 settlement shed 01 cents or 0.01% to $74.42 a barrel. Stocks in Spotlight: Granules India shed 0.30%. The company said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Switzerland based company, for a total consideration of Rs 192.5 crore (CHF 20 million). Lupin fell 0.34%. The company said that it has received establishment inspection report (EIR) from the US Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, USA. Bharti Airtel declined 0.35%. The company said that its board has approved to acquire additional 5% stake in Airtel Africa, wholly owned subsidiary, through Airtel Africa Mauritius (AAML) in one or more tranches during FY24-25. Global Markets: US Dow Jones index futures were up 193 points, with focus now turning to upcoming earnings from artificial intelligence darling Nvidia. Asian shares traded mixed performance on Monday, mirroring Wall Street's sharpest decline of the year. US economic data revealed weakening service sector activity and diminished consumer sentiment, fueling concerns about a potential slowdown and its impact on corporate earnings. Additionally, renewed inflation worries and unease stemming from a new bat coronavirus study in China contributed to market volatility. The euro, however, strengthened following Germany's conservative party's victory in national elections. US indices experienced significant losses Friday, triggered by disappointing service sector PMI and consumer sentiment figures. These data points heightened apprehension about a cooling US economy. While weaker growth could prompt the Federal Reserve to consider interest rate cuts, it also raises the possibility of a less favorable business climate, potentially affecting corporate profitability. Economic uncertainty was further amplified by the possibility of new 25% tariffs on automobile, pharmaceutical, semiconductor, and lumber imports. The S&P 500 fell 1.7% to 6,013.13, the NASDAQ Composite dropped 2.2% to 19,524.01, and the Dow Jones Industrial Average decreased 1.7% to 43,428.02. S&P Global's preliminary composite purchasing managers' index for the US declined to 50.4 in February from 52.7 in January, with the services PMI falling to 49.7 from 52.9. The University of Michigan's sentiment index showed US consumer sentiment weakened in February, registering 64.7, down from 71.1. NVIDIA Corporation shares fell 4.1% on Friday, reflecting growing anticipation and uncertainty ahead of the company's earnings release this week.Powered by Capital Market - Live

Securities in F&O Ban: Manappuram Finance and Chambal Fertilisers & Chemicals shares are banned from F&O Trading on 24 February 2025. Stocks to Watch: Granules India said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Switzerland based company, for a total consideration of Rs 192.5 crore (CHF 20 million). Lupin said that it has received establishment inspection report (EIR) from the US Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, USA. The Index Maintenance Sub-Committee (Equity) of NSE Indices has decided to make replacement of stocks in various indices as part of its periodic review as listed hereunder. These changes shall become effective from 28 March 2025 (close of 27 March 2025). According to latest press release issued the NSE Indices, Bharat Petroleum Corporation (BPCL) and Britannia Industries have been excluded from the Nifty 50 index. They are being replaced by Jio Financial Services and Zomato. Bharti Airtel said that its board has approved to acquire additional 5% stake in Airtel Africa, wholly owned subsidiary, through Airtel Africa Mauritius (AAML) in one or more tranches during FY24-25. Hazoor Multi Projects said that it has secured a work order worth Rs 102.10 crore from Venkatesh Infra Projects. Rail Vikas Nigam (RVNL) has emerged as the lowest bidder (L1) for the supply of a 2x25 KV overhead equipment (OHE) and power supply installation (PSI) system from South Western Railway, with the project valued at Rs 156.35 crore. Lemon Tree Hotels announced that it has signed a license agreement viz. Lemon Tree Resort, Chittorgarh, Rajasthan.Powered by Capital Market - Live

Granules India today announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025. The acquisition brings Senn's expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments. Senn's manufacturing facility is certified under ISO 9001:2015 and is regularly inspected and approved for cGMP production by Swissmedic. Under the Mutual Recognition Agreement (MRA) between Swissmedic and the U.S. Food and Drug Administration (FDA), cGMP inspections conducted by Swissmedic are recognized by the FDA. This acquisition enables Granules' acquiring capabilities into high-growth peptidebased therapeutics. The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn's R&D capabilities. The acquisition marks Granules foray into CDMO segments, leveraging Senn's existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn's European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules' global footprint. By integrating Senn's capabilities with Granules' expertise in large-scale, cost-efficient manufacturing, Granules aim to become a key player in development and manufacturing of peptide-based applications across Pharmaceuticals, cosmetics and theragnostic segments industries, spanning the entire value chain from AADs and Peptide fragments to peptide-based active ingredients. Powered by Capital Market - Live

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactures, Peptides and peptides based applications for its global customers, providing contract research, development, and manufacturing services. Its revenue for CY23 was CHF 26.9 million and it had estimated sales of CHF 19.6 million in the calendar year (CY) 2024. The acquisition brings Senn's expertise in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments. This acquisition enables Granules' acquiring capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn's R&D capabilities. The transaction is expected to be completed in the first half of calendar year 2025. Krishna Prasad Chigurupati, chairman & managing director, Granules India, said, The acquisition of Senn Chemicals AG marks a significant milestone in Granules' strategic growth journey. By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn's expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally. This acquisition is a pivotal moment in our vision to transform Granules to a science and innovation led organization and become a trusted partner in complex and specialized therapeutics. Rico Wiedenbruch, chairman, Senn Chemicals AG, said, We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules' scale, operational efficiency, and global reach in pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics. This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing. Meanwhile, the company's board approved incorporation of a wholly owned subsidiary in India for the aforementioned acquisition. The name of the proposed wholly-owned subsidiary (WOS) will be as approved by the Ministry of Corporate Affairs (MCA), Government of India. The company shall be incorporated with an authorized share capital of Rs 500 crore and a paid-up share capital of Rs 200 crore. Granules India is primarily involved in the manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company's consolidated net profit fell 6.41% to Rs 117.60 crore on 1.55% decline in total revenue from operations to Rs 1,137.70 crore in Q3 FY25 over Q3 FY24. The counter declined 3.48% to end at Rs 509 on Friday, 21 February 2025.Powered by Capital Market - Live

Granules India announced that Riaz Ahmed, shall cease to be the Senior Management Personnel (SMP) of the Company upon his resignation from the position of Senior Vice President & Head- Supply Chain Management with effect from the closure of business hours of 03 February 2025. Powered by Capital Market - Live